Clinical trials: Untreated
Chronic Lymphocytic Leukemia
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
This phase I/II trial will combine fludarabine, rituximab, and lenalidomide in untreated or minimally treated (Phase I only) CLL patients, employing fixed doses of fludarabine and rituximab, using a schedule similar to that…
- Trial name
- NCT00536341
- Testing
- lenalidomide, Rituximab, Fludarabine
- Where
- 6 sites in United States
- Volunteers
- 64 people
- Sponsor
- SCRI Development Innovations, LLC
Multiple Myeloma
Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.
This phase 2 study will be conducted at 10 centers and enroll patients from August 2013 to August 2017.Firstly, All patients included will provide written informed consent.
- Trial name
- NCT02086942
- Testing
- Bortezomib, cyclophosphamide, Dexamethasone
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Yongping Zhai
Chronic Lymphocytic Leukemia
Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)
A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by ofatumumab and ibrutinib followed by ibrutinib and ofatumumab maintenance in CLL…
- Trial name
- NCT02689141
- Testing
- Bendamustine, Ofatumumab, Ibrutinib
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- German CLL Study Group
Moderate-severe Skin Aging/Photoaging
Efficacy and Tolerance Evaluation of an Anti-age Food Supplement
Efficacy and Tolerance Evaluation of an Anti-age Food Supplement: a Randomized, Controlled Clinical Study Versus Untreated Group
- Trial name
- NCT03274154
- Testing
- Pre-Hyaluron 465 Innēov
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Derming SRL
Extensive Disease, First-Line
Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)
Randomised trial comparing standard chemotherapy with carboplatin and etoposide with a combination of topotecan and cisplatin in patients with inoperable lung cancer of small cell type.
- Conditions
- Extensive Disease, First-Line, Small Cell Lung Cancer
- Trial name
- NCT00812266
- Testing
- topotecan + cisplatin, Etoposide + carboplatin
- Where
- Denmark
- Volunteers
- 281 people
- Sponsor
- Danish Oncological Lung Cancer Group
Lung Cancer
Progression of Untreated Pulmonary Ground Glass Opacity
In this study, about 2000 GGO patients will be included for a 5-year follow-up. The aim of this study is to elucidate the biological nature of pulmonary GGO lesion and provide evidence for GGO treatment.
- Trial name
- NCT03723629
- Testing
- No intercention
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Shanghai Zhongshan Hospital
Colorectal Cancer
OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer
This single arm study will assess progression-free survival, feasibility of use and safety of Avastin in combination with 5-FU/FA, oxaliplatin and irinotecan (FOLFOXIRI) as first line treatment in patients with metastatic…
- Trial name
- NCT00940303
- Testing
- 5-FU, bevacizumab [Avastin], irinotecan
- Where
- 17 sites in Germany
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer, Endometrial Cancer
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 and/or sargramostim may be a more effective treatment for solid tumors.
- Conditions
- Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00019331
- Testing
- aldesleukin, ras peptide cancer vaccine, sargramostim
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
First Episode Psychosis
Reducing the Duration of Untreated Psychosis
The study examines the possible effect of a community campaign to decrease the duration of untreated psychosis in persons with their first episode of a psychotic disorder.
- Trial name
- ReduceDUP (NCT03102151)
- Testing
- Community Campaign La CLAVE
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- University of Southern California
Peripheral T-Cell Lymphoma, Lenalidomide
Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
This study aims to compare the efficacy and safety of lenalidomide plus CHOP (L-CHOP) versus CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL)
- Conditions
- Peripheral T-Cell Lymphoma, Lenalidomide, CHOP
- Trial name
- NCT04922567
- Testing
- Lenalidomide, Cyclophosphamide, Doxorubicin
- Where
- China
- Volunteers
- 289 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colorectal Cancer
Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00797485
- Testing
- bevacizumab, capecitabine, fluorouracil
- Where
- Italy
- Volunteers
- 672 people
- Sponsor
- Southern Italy Cooperative Oncology Group
Non-Small Cell Lung Cancer
A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab
This is a phase 2 multicenter, open label, randomized study of AMG 951 (rhApo2L/TRAIL) in subjects with previously untreated stage IIIb/IV NSCLC treated with chemotherapy with or without bevacizumab.
- Trial name
- NCT00508625
- Testing
- AMG 951 (rhApo2L/TRAIL), Bevacizumab, Carboplatin
- Volunteers
- 213 people
- Sponsor
- Amgen
Leukemia
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
RATIONALE: Nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or…
- Trial name
- NCT00844298
- Testing
- Nilotinib+mVPD
- Where
- 16 sites in South Korea
- Volunteers
- 91 people
- Sponsor
- Asan Medical Center
Diffuse Large B Cell Lymphoma (DLBCL)
Dynamic CtDNA-guided Targeted Therapy in DLBCL
This is a prospective, single-arm, noninferiority trial involving patients with previously untreated CD20-positive DLBCL. The aim of this study is to determine the efficacy and safety of treatment stratified based on ctDNA…
- Trial name
- NCT06748521
- Testing
- R-CHOP + X
- Volunteers
- 108 people
- Sponsor
- Ruijin Hospital
Lymphoma, Malignant
Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma
Combination of involved field radiotherapy for the control of macroscopic disease and CD20 antibody Rituximab for the control of microscopic remainders in other regions in patients with early stage nodal follicular lymphoma…
- Trial name
- MIR (NCT00509184)
- Testing
- Rituximab
- Where
- 17 sites in Germany
- Volunteers
- 85 people
- Sponsor
- Klaus Herfarth, MD
Biliary Tract Cancer
A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer
This study will evaluate the efficacy and safety of atezolizumab with bevacizumab in combination with cisplatin and gemcitabine(CisGem), compared with atezolizumab in combination with CisGem, in participants with advanced biliary…
- Trial name
- NCT04677504
- Testing
- Atezolizumab, Bevacizumab, Cisplatin
- Where
- 49 sites in United States, China and 11 more
- Volunteers
- 162 people
- Sponsor
- Hoffmann-La Roche
Cognitive/Functional Effects, Depression
Physical and Mental Assessment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: Learning about physical ability and mental function over time in older patients with acute myeloid leukemia may help doctors learn about the long-term effects of treatment and plan the best treatment.
- Conditions
- Cognitive/Functional Effects, Depression, Leukemia
- Trial name
- NCT00499785
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Wake Forest University Health Sciences
Brain and Central Nervous System Tumors, Gastrointestinal Stromal Tumor
Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood.
- Conditions
- Brain and Central Nervous System Tumors, Gastrointestinal Stromal Tumor, Sarcoma
- Trial name
- NCT00069940
- Testing
- sargramostim, telomerase: 540-548 peptide vaccine
- Where
- United States
- Sponsor
- Dana-Farber Cancer Institute
Pancreatic Cancer
Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00550836
- Testing
- panitumumab, erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 262 sites in United States
- Volunteers
- 104 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Diffuse Large B-Cell Lymphoma
A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.
This multicenter, open-label study will assess the efficacy and safety of MabThera (rituximab) added to standard chemotherapy in participants with untreated Mantle Cell Lymphoma not eligible for autologous stem cell…
- Trial name
- NCT01144403
- Testing
- Cyclophosphamide, Fludarabine, Mitoxantrone
- Where
- 8 sites in Romania
- Volunteers
- 8 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.